• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[F]FDG PET/CT 在初诊转移性激素敏感型前列腺癌中的预后价值：一项回顾性队列研究。

Prognostic value of [F]FDG PET/CT in metastatic hormone-sensitive prostate cancer at initial diagnosis: a retrospective cohort study.

机构信息

Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Department of Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

出版信息

Ann Med. 2024 Dec;56(1):2411017. doi: 10.1080/07853890.2024.2411017. Epub 2024 Oct 11.

DOI:10.1080/07853890.2024.2411017
PMID:39392016
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11485890/
Abstract

INTRODUCTION

This retrospective study aimed to evaluate the prognostic value of [F]FDG parameters in patients with visceral and bone metastatic hormone-sensitive prostate cancer (mHSPC).

PATIENTS AND METHODS

This analysis included the mHSPC patients who underwent [F]FDG PET/CT at the initial diagnosis. Baseline characteristics were analyzed, and the uptake of [F]FDG was quantified using SUV. Kaplan-Meier and Cox proportional hazard regression analysis were employed to evaluate the correlation between SUV and patient survival.

RESULTS

Among the 267 patients enrolled, 90 (33.7%) presented with visceral metastases and 177 (66.3%) had bone metastases. The median follow-up for the visceral metastasis group was 35.5 months (IQR 26-53.8 months). The median overall survival for patients with lung, liver, or both metastases were 30, 21 and 17 months, respectively. Patients exhibiting higher [F]FDG uptake in metastatic lesions experienced shorter overall survival (OS) in comparison to those with lower [F]FDG uptake, both in the visceral metastases group (17 vs. 31 months,  = 0.002) and the bone metastases group (27.5 vs. 34.5 months,  < 0.001). Cox regression analysis further revealed that increased [F]FDG uptake in metastatic lesions emerged as a significant risk factor in both OS and progression-free survival (PFS). In contrast, the variability in [F]FDG uptake in primary lesions did not provide a reliable indicator for predicting prognosis.

CONCLUSIONS

In mHSPC patients, higher [F]FDG uptake in metastatic lesions indicates shorter survival and increased risk of disease progression. The [F]FDG SUV in primary tumors did not show significant prognostic value. Our study underscores the unique prognostic potential of [F]FDG PET/CT in mHSPC patients, highlighting its importance in the management of both bone and visceral metastases.

摘要

简介

本回顾性研究旨在评估 [F]FDG 参数在有内脏和骨转移的激素敏感前列腺癌（mHSPC）患者中的预后价值。

患者和方法

本分析纳入了在初始诊断时接受 [F]FDG PET/CT 的 mHSPC 患者。分析了基线特征，并使用 SUV 量化 [F]FDG 的摄取。采用 Kaplan-Meier 和 Cox 比例风险回归分析评估 SUV 与患者生存之间的相关性。

结果

在纳入的 267 例患者中，90 例（33.7%）有内脏转移，177 例（66.3%）有骨转移。内脏转移组的中位随访时间为 35.5 个月（IQR 26-53.8 个月）。肺、肝或两者均有转移的患者的总生存中位数分别为 30、21 和 17 个月。与 [F]FDG 摄取较低的患者相比，转移性病变中 [F]FDG 摄取较高的患者总生存（OS）更短，在有内脏转移的患者中（17 与 31 个月，  = 0.002）和有骨转移的患者中（27.5 与 34.5 个月，  < 0.001）。Cox 回归分析进一步表明，转移性病变中 [F]FDG 摄取的增加是 OS 和无进展生存（PFS）的显著危险因素。相比之下，原发肿瘤中 [F]FDG 摄取的变化并不能为预测预后提供可靠指标。

结论

在 mHSPC 患者中，转移性病变中 [F]FDG 摄取较高提示生存时间较短，疾病进展风险增加。原发肿瘤中 [F]FDG SUV 无显著预后价值。本研究强调了 [F]FDG PET/CT 在 mHSPC 患者中的独特预后潜力，突出了其在骨转移和内脏转移管理中的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/07ab43358f57/IANN_A_2411017_F0006_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/c3bed9a2e9c9/IANN_A_2411017_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/503649373d92/IANN_A_2411017_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/1d76b221f963/IANN_A_2411017_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/ba0c52398f46/IANN_A_2411017_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/11b785be9a97/IANN_A_2411017_F0005_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/07ab43358f57/IANN_A_2411017_F0006_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/c3bed9a2e9c9/IANN_A_2411017_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/503649373d92/IANN_A_2411017_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/1d76b221f963/IANN_A_2411017_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/ba0c52398f46/IANN_A_2411017_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/11b785be9a97/IANN_A_2411017_F0005_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430b/11485890/07ab43358f57/IANN_A_2411017_F0006_C.jpg

相似文献

1
Prognostic value of [F]FDG PET/CT in metastatic hormone-sensitive prostate cancer at initial diagnosis: a retrospective cohort study.[F]FDG PET/CT 在初诊转移性激素敏感型前列腺癌中的预后价值：一项回顾性队列研究。
Ann Med. 2024 Dec;56(1):2411017. doi: 10.1080/07853890.2024.2411017. Epub 2024 Oct 11.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer.定量氟脱氧葡萄糖测量在新诊断转移性乳腺癌中的预后价值。
Cancer Med. 2013 Oct;2(5):725-33. doi: 10.1002/cam4.119. Epub 2013 Sep 12.
4
Prognostic Value of F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.F-FDG PET/CT 在接受肽受体放射性核素治疗的晚期转移性神经内分泌肿瘤患者中的大型队列中的预后价值。
J Nucl Med. 2020 Nov;61(11):1560-1569. doi: 10.2967/jnumed.119.241414. Epub 2020 Mar 13.
5
Prospective Study of Serial F-FDG PET and F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer.前瞻性研究 F-FDG PET 和 F-氟化物 PET 预测骨转移乳腺癌患者的骨骼相关事件时间、进展时间和生存时间。
J Nucl Med. 2018 Dec;59(12):1823-1830. doi: 10.2967/jnumed.118.211102. Epub 2018 May 10.
6
Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by F-FDG PET/CT. The role of Tc-MDP.通过F-FDG PET/CT研究发现，乳腺癌和前列腺癌骨转移灶中的代谢活性相似。锝-亚甲基二膦酸盐（Tc-MDP）的作用。
Hell J Nucl Med. 2017 Sep-Dec;20(3):237-240. doi: 10.1967/s002449910608. Epub 2017 Nov 27.
7
Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUV in [F]fluoride and [F]FDG PET?与氟[F]脱氧葡萄糖（FDG）和氟[F]氟代胸腺嘧啶（FLT）PET 相比，测量一级和异质性参数是否可改善乳腺癌骨转移的反应评估？
Mol Imaging Biol. 2019 Aug;21(4):781-789. doi: 10.1007/s11307-018-1262-3.
8
High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.18F-FDG PET 对转移性胃肠胰腺神经内分泌肿瘤具有高预后价值：一项长期评估。
J Nucl Med. 2014 Nov;55(11):1786-90. doi: 10.2967/jnumed.114.144386. Epub 2014 Oct 6.
9
The Prognostic Value of Posttreatment Ga-PSMA-11 PET/CT and F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).在 Lu-PSMA-617 和 NOX66 治疗的转移性去势抵抗性前列腺癌的 I/II 期试验（LuPIN）中，治疗后 Ga-PSMA-11 PET/CT 和 F-FDG PET/CT 的预后价值。
J Nucl Med. 2023 Jan;64(1):69-74. doi: 10.2967/jnumed.122.264104. Epub 2022 Jun 23.
10
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study.采用 F-FDG PET 参数对转移性前列腺癌全身肿瘤负荷进行定量评估，并与一线阿比特龙或恩杂鲁胺治疗后的总生存相关：一项单中心回顾性队列研究。
J Nucl Med. 2021 Aug 1;62(8):1050-1056. doi: 10.2967/jnumed.120.256602. Epub 2021 Jan 8.

本文引用的文献

1
MRI and PSMA PET/CT of Biochemical Recurrence of Prostate Cancer.磁共振成像和 PSMA PET/CT 对前列腺癌生化复发的诊断。
Radiographics. 2023 Dec;43(12):e230112. doi: 10.1148/rg.230112.
2
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.NCCN 指南®洞察：前列腺癌，第 1.2023 版。
J Natl Compr Canc Netw. 2022 Dec;20(12):1288-1298. doi: 10.6004/jnccn.2022.0063.
3
Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.伴有内脏转移的去势抵抗性前列腺癌患者的发病率和生存率：来自荷兰CAPRI注册研究的结果。
Prostate Cancer Prostatic Dis. 2023 Mar;26(1):162-169. doi: 10.1038/s41391-022-00605-7. Epub 2022 Oct 12.
4
The Evolving Role of F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer.F-FDG PET/CT在进展期前列腺癌诊断及预后预测中的作用演变
Front Oncol. 2021 Jul 29;11:683793. doi: 10.3389/fonc.2021.683793. eCollection 2021.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
Clinical Utility of F-FDG PET/CT for Staging and Treatment Planning in Urachal Adenocarcinoma.F-FDG PET/CT 对脐尿管腺癌分期和治疗计划的临床应用价值。
J Nucl Med. 2021 May 10;62(5):643-647. doi: 10.2967/jnumed.120.251561. Epub 2020 Sep 18.
7
Epidemiology of liver metastases.肝转移瘤的流行病学。
Cancer Epidemiol. 2020 Aug;67:101760. doi: 10.1016/j.canep.2020.101760. Epub 2020 Jun 17.
8
Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: A study of 1358 patients.不同部位特异性内脏转移的前列腺癌患者总生存的预后因素：一项对1358例患者的研究
World J Clin Cases. 2020 Jan 6;8(1):54-67. doi: 10.12998/wjcc.v8.i1.54.
9
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
10
Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe.全球转移性激素敏感型前列腺癌的医疗保健服务提供。
Eur Urol Focus. 2019 Mar;5(2):155-158. doi: 10.1016/j.euf.2018.12.003. Epub 2018 Dec 23.